Polyrizon amends patent application claims for intranasal drug delivery platform

Polyrizon (PLRZ) announced the submission of amended claims in its U.S. patent application for its proprietary intranasal drug delivery platform. The amended claims expand the scope of protection of the company’s technology to include not only the core mucoadhesive composition, but also drug delivery systems and methods of use, which are designed to enhance the effectiveness of medications by increasing their residence time and ensuring close contact with mucosal tissues. The expanded claims relate to compositions comprising sulfated polysaccharide polymers and additional polymeric components that form a uniform and continuous film upon contact with epithelial mucosa.